RANI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:54):

Stats
Šios dienos apimtis	257 154
Vidutinė apimtis	134 662
Rinkos kapitalizacija	319.63M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $-0.200 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.77
ATR14	$0.0140 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Mckinley Kate	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Hashim Mir	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Groen Eric	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Imran Talat	Buy	1 085 000	Stock Option (Right to Buy)
2024-03-21	Sanford Svai S	Buy	323 500	Stock Option (Right to Buy)

INSIDER POWER
19.25
Last 99 transactions
Buy: 12 150 348 \| Sell: 8 157 844

Tūris Koreliacija

Ilgas: -0.11 (neutral)

Trumpas: -0.40 (neutral)

Signal:(48.521) Neutral

Rani Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LWAY	0.823

10 Labiausiai neigiamai susiję koreliacijos
FAT	-0.836
APPF	-0.832
FSTR	-0.826
DATS	-0.825
ENTG	-0.825
ALGT	-0.818

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Rani Therapeutics Koreliacija - Valiuta/Žaliavos

0.56
( weak )

0.53
( weak )

0.00
( neutral )

0.54
( weak )

-0.75
( moderate negative )

-0.77
( moderate negative )

Rani Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2023
Pajamos:	$0
Bruto pelnas:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.31M (0.00 %)
EPS:	$-2.66

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.445

Financial Reports:

No articles found.

Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.